A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin
Conclusions The initial safety profile of LY2090314 was established. MTD LY dose with pemetrexed/carboplatin is 40 mg IV every 3 weeks plus ranitidine. Efficacy of LY plus pemetrexed/carboplatin requires confirmation in randomized trials.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Alimta | Asbestosis | Back Pain | Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Investigational New Drugs | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Pain | Ranitidine | Study | Thrombocytopenia | Toxicology